WellPoint to cover shingles vaccine
WellPoint Inc. announced that effective immediately it will cover the vaccine Zostavax (zoster vaccine, live [Oka, Merck]), designed to prevent shingles (herpes zoster), a painful condition resulting from the reactivation of the chickenpox virus, typically in older individuals. The vaccine will be covered for individuals 60 years of age and older whose benefit plans provide coverage for vaccines. WellPoint already provides benefits for Zostavax through its Medicare Part D benefit based on the FDA's licensure of Zostavax this past May. Specific benefit plans may have variable benefits for immunizations.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
